The Mayne Pharma Group Ltd (ASX: MYX) share price jumped 18.87% higher in yesterday’s trade after a significant announcement from the Aussie pharmaceuticals group.
What did Mayne Pharma announce yesterday?
Before yesterday’s market open, Mayne Pharma announced that it had signed an exclusive license and supply agreement for an oral contraceptive with its long-term partner, Mithra Pharmaceuticals.
The two pharmaceutical groups announced strong expected earnings from E4/DRSP, following the applicable regulatory approvals, with a big expected boost from US sales.
The company expects to have the new, commercialised contraceptive product on sale from as early as 2021 with the potential to realise peak net sales of US$200 million per year or more.
Should you buy Mayne Pharma shares?
Given management put the value of the US contraceptive market at US$5.4 billion (A$8.05 billion), it’s hard to say what the long-term prospects of Mayne Pharma are at the moment.
While this new product launch with Mithra should boost earnings (assuming it is approved for sale), my concern is that the Mayne Pharma share price has more than halved in the last 12 months.
The ASX Healthcare sector could be a great place to diversify into given its historically defensive nature, but I think there could be better options than Mayne Pharma at the moment.
What are some alternatives to Mayne Pharma?
If you’re interested in buying some ASX healthcare stocks, I think CSL Limited (ASX: CSL) could be a good option at the moment.
While the CSL share price is currently valued at $234.65 and not far from its 52-week high, it has also climbed 218.30% higher in the last 5 years.
The company also pays a 0.98% per annum dividend yield and boasts a market cap of $106.5 billion, but does have a price-to-earnings ratio of 37.6x, which is a little lofty.
Another option amongst the large-cap ASX healthcare stocks is Ramsay Health Care Limited (ASX: RHC), which has seen some strong share price growth of its own in 2019.
For those wanting some other strong dividend options, I'd check out these 3 high-yield stocks below.
With interest rates likely to stay at rock bottom for months (or YEARS) to come, income-minded investors have nowhere to turn... except dividend shares. That’s why The Motley Fool’s top analysts have just prepared a brand-new report, laying out their top 3 dividend bets for 2019.
Hint: These are 3 shares you’ve probably never come across before.
They’re not the banks. Not Woolies or Wesfarmers or any of the “usual suspects.”
We think these 3 shares offer solid growth prospects over the next 12 months. Each of these three companies boasts fully franked yields and could be a great fit for your diversified portfolio. You’ll discover all three names and codes in "The Motley Fool’s Top 3 Dividend Shares for 2019."
Even better, your copy is free when you click the link below. Fair warning: This report is brand new and may not be available forever. Click the link below to be among the first investors to get access to this timely, important new research!
The names of these top 3 dividend bets are all included. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies move – we may be forced to remove this report.
Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.